Ethylene oxide (EO) residue determination is a mandatory safety test for EO-sterilized medical devices, verifying that residual EO and its by-product ethylene chlorohydrin (ECH) remain within the biologically safe limits defined by ISO 10993-7 and GB/T 16886.7. This article explains the technical basis, sample requirements, headspace gas chromatography methods, acceptance limits, and typical applications of EO residual testing for sterilization validation and regulatory compliance.
Technical Overview
Ethylene oxide (EO) sterilization remains the dominant low-temperature sterilization modality for medical devices that are sensitive to heat and moisture. EO gas penetrates breathable sterile packaging and is compatible with a wide range of polymeric materials, which makes it indispensable for single-use consumables and many implantable products. However, EO and its reaction by-products—ethylene chlorohydrin (ECH, 2-chloroethanol) and, to a lesser extent, ethylene glycol (EG)—are adsorbed within device materials and can diffuse out during clinical use.
Residual EO is biologically hazardous: it is a mucosal irritant, a sensitizer, a genotoxic agent, and is classified as a known human carcinogen by international health authorities. ECH is similarly toxic. For this reason, every EO-sterilized device must be evaluated to demonstrate that residues released to the patient remain below established allowable limits before the product is released to market.
The core framework for this evaluation is provided by ISO 10993-7 (adopted in China as GB/T 16886.7), which defines tolerable exposure limits, extraction strategies, and chromatographic determination methods. In addition, ISO 11135, which governs the validation and routine control of EO sterilization processes, requires demonstration that aeration reduces residues to acceptable levels. Determination is typically performed by headspace gas chromatography (HS-GC) with flame ionization detection (FID) or mass spectrometric detection (GC-MS) after simulated-use or exhaustive extraction.
- ISO 10993-7:2008 / EN ISO 10993-7 — Biological evaluation of medical devices, Part 7: Ethylene oxide sterilization residuals (limits and evaluation principles)
- GB/T 16886.7-2015 — Chinese national adoption of ISO 10993-7 with identical technical content
- ISO 11135:2014 / GB 18279.1-2015 — Validation and routine control of ethylene oxide sterilization, including aeration and residual requirements
- GB/T 14233.1-2022 — Chemical analysis methods for infusion, transfusion and injection equipment, including EO residue determination
- ISO 11979 series — Ophthalmic implant standards specifying the special, significantly lower EO limit for intraocular lenses
Testing Samples
Single-Use Sterile Devices
This category represents the largest volume of EO residual testing. Typical samples include syringes, infusion and blood transfusion sets, hemodialyzers, blood oxygenators, extracorporeal circuit tubing, urinary and intravascular catheters, endotracheal tubes, urine and drainage bags, wound dressings, surgical gowns and drapes, and absorbable or non-absorbable sutures.
Implantable and Prolonged-Contact Devices
Hernia repair meshes, cardiac occluders, polymer-based orthopedic components, intraocular lenses, and drug-device combination products fall under stricter exposure categories because patient contact persists beyond 24 hours or is permanent. These devices usually require exhaustive extraction and conservative dose calculations.
Raw Materials, Components and Packaging
Polymer granules, extruded tubing, adhesive-bonded subassemblies, potting compounds, thermoformed trays, and microporous breathable packaging films may be tested to characterize EO affinity, support product-family grouping, or evaluate the influence of packaging on desorption behavior during aeration.
Sampling and Sample Integrity
Because EO is volatile and continues to desorb after sterilization, sample integrity is critical. Worst-case samples should be selected based on the most adsorptive materials (such as PVC, polyurethane and silicone), the greatest mass and thickness, the most confining packaging, and the position in the sterilization load with the slowest aeration. Samples must be sealed in gas-tight containers (for example, foil laminate bags), transported under refrigeration at 2–8 °C, and analyzed promptly by an accredited third-party laboratory, with the elapsed time between sterilization and testing documented.
Testing Items
EO residual evaluation encompasses the following measurands and assessments, reported with clear traceability to the applicable standard:
- Ethylene oxide (EO) residue content, expressed as mg per device or µg per gram of material
- Ethylene chlorohydrin (ECH) residue content, expressed as mg per device
- Ethylene glycol (EG) content where contractually or toxicologically justified (generally of low regulatory concern under ISO 10993-7)
- Patient dose calculation and compliance assessment against the applicable exposure-duration category of ISO 10993-7 / GB/T 16886.7
- Multi-timepoint desorption (aeration) curve studies to establish release timepoints during sterilization validation
Testing Methods
Extraction Procedures
Two extraction strategies are recognized. Simulated-use extraction models the actual clinical exposure: the device, or a defined portion of it, is immersed in a measured volume of water and extracted at 37 ± 1 °C for one hour, with the resulting solution representing the dose delivered to the patient in a single day. Exhaustive extraction is applied where total residual burden is relevant, typically for implants; the sample is extracted repeatedly until the residue in the final extract is less than 10 percent of the first extraction or the cumulative total exceeds 90 percent of the asymptotic value. Water is the preferred extraction medium, although alternative validated solvents may be used for materials that strongly retain EO.
Headspace Gas Chromatography with FID
Headspace GC-FID is the reference technique. Aliquots of the extract are sealed in headspace vials, equilibrated at an elevated temperature (typically 60–90 °C) to drive EO into the headspace, and injected onto a capillary column of the 624-type or equivalent. Quantification is performed by multi-point external calibration against freshly prepared EO and ECH reference solutions, with peak identity confirmed by retention time and, where necessary, dual-column confirmation.
GC-MS Confirmation
Gas chromatography coupled with mass spectrometry in selected-ion monitoring mode provides unambiguous identification in complex matrices, improves selectivity against co-eluting extractables, and achieves lower detection limits, which is valuable when residues must be quantified far below the acceptance limit.
Calibration, Calculation and Data Evaluation
Calibration curves are prepared gravimetrically across the expected concentration range, with linearity typically demonstrated by a correlation coefficient of 0.995 or better. The measured concentration in the extract is multiplied by the extraction volume and any dilution factor to obtain the residue per device, then converted to a daily patient dose by considering the number of devices used per day. The calculated dose is compared with the allowable limit for the relevant contact duration category.
Method Validation and Quality Control
Validated methods must demonstrate specificity, linearity, accuracy (spike recovery typically within 85–115 percent), precision (repeatability RSD generally not exceeding 10 percent), limits of detection and quantification below one tenth of the applicable limit, and robustness. Each analytical batch includes method blanks, duplicate determinations, calibration verification standards, and spiked quality-control samples. Laboratories are expected to operate under ISO/IEC 17025-accredited quality systems and to participate in relevant proficiency testing schemes.
Applications
EO residue determination supports the full product lifecycle, from process development to post-market surveillance:
- Sterilization process validation under ISO 11135, including aeration cycle design, desorption-curve studies, and establishment of product release timepoints
- Routine batch release and periodic residual verification as part of ongoing process monitoring
- Regulatory registration submissions for market access in China, the European Union, North America and other jurisdictions
- Change control following modifications to materials, suppliers, packaging, load configuration, or sterilization cycle parameters
- Shelf-life and stability studies confirming that residues remain compliant throughout the claimed expiry period
- Post-market surveillance, complaint investigation, and root-cause analysis of unexpected residual findings
- Scientific justification of product families and worst-case sample selection, and support for reduced-aeration or parametric release strategies
FAQ
What are the allowable limits for EO and ECH residues?
Under ISO 10993-7 and GB/T 16886.7, for devices with patient contact of 24 hours or less, the limits are 4 mg EO and 9 mg ECH per device. For prolonged exposure between 24 hours and 30 days, the allowable dose is 2 mg plus 0.1 mg per additional day for EO, and 9 mg plus 2.2 mg per additional day for ECH. For permanent contact beyond 30 days, the average daily dose must not exceed 0.1 mg/day for EO and 2.2 mg/day for ECH. Intraocular lenses are subject to a special limit of 0.5 µg EO per device.
When should samples be tested after sterilization?
Because EO desorbs continuously, results are time-dependent. During validation, samples are tested at several defined intervals to construct the aeration curve and confirm the release timepoint. For routine verification, testing is performed according to the documented protocol at the point of product release, and the elapsed time between sterilization and analysis is always recorded.
When is simulated-use extraction used instead of exhaustive extraction?
Simulated-use extraction is appropriate for devices that contact aqueous body fluids during use, since it directly estimates the clinically delivered dose. Exhaustive extraction is applied to implants and devices where the total residual burden is the relevant measure, or where simulated-use conditions cannot adequately recover adsorbed residues.
Can one test result cover an entire product family?
Yes, provided a documented worst-case rationale exists. Representative testing is acceptable when the selected sample reflects the highest EO affinity, greatest mass, slowest aeration, and longest patient contact within the family. Re-testing is required whenever materials, packaging, or cycle parameters change the worst-case configuration.
Is ECH always tested together with EO?
In most cases yes, because ECH is formed whenever EO reacts with chloride-containing species and its limit is of the same regulatory significance. EG is generally of lower toxicological concern and is not routinely required under ISO 10993-7 unless specifically justified.
How should samples be shipped to the laboratory?
Samples should remain in their original sterile packaging or be transferred to gas-tight foil laminate bags, kept at 2–8 °C during transport, and delivered to the testing laboratory without delay. Each submission should include sterilization records, aeration history, sterilization date, and intended clinical use so that the correct exposure category is applied during evaluation.